We are live on ! Find out more
SPRY icon

ARS Pharmaceuticals
SPRY

62 hedge funds and large institutions have $1.13B invested in ARS Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 62 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

70.26% more ownership

Funds ownership: 0% → 70.26% (+70%)

Holders
62
Holders Change
+62
Holders Change %
–
% of All Funds
1.1%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.07%
New
62
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$292M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$115M
3
EC
EcoR1 Capital
California
+$84.6M
4
RCM
RA Capital Management
Massachusetts
+$58.2M
5
BC
Boxer Capital
California
+$56M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$405M +$292M +8,740,887 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$156M +$115M +3,441,304 New
EC
3
EcoR1 Capital
California
$117M +$84.6M +2,533,635 New
RCM
4
RA Capital Management
Massachusetts
$80.7M +$58.2M +1,742,186 New
BC
5
Boxer Capital
California
$77.6M +$56M +1,675,377 New
NCM
6
Nantahala Capital Management
Connecticut
$54.4M +$40.3M +1,206,471 New
CAM
7
Cormorant Asset Management
Massachusetts
$23.2M +$16.7M +500,000 New
Ameriprise
8
Ameriprise
Minnesota
$19.8M +$14.3M +428,714 New
BlackRock
9
BlackRock
New York
$18.1M +$13M +390,161 New
EAM
10
Eventide Asset Management
Massachusetts
$15.8M +$11.4M +341,473 New
LGM
11
Logos Global Management
California
$13.9M +$10M +300,000 New
BBA
12
Baker Bros. Advisors
New York
$11M +$7.95M +238,095 New
WP
13
Woodline Partners
California
$9.99M +$7.2M +215,536 New
WA
14
Wasatch Advisors
Utah
$9.72M +$7M +209,695 New
Franklin Resources
15
Franklin Resources
California
$9.27M +$6.68M +200,008 New
PHS
16
PFM Health Sciences
California
$8.72M +$6.29M +188,243 New
SFM
17
Sphera Funds Management
Israel
$8.07M +$5.82M +174,261 New
Millennium Management
18
Millennium Management
New York
$7.69M +$5.55M +166,039 New
VA
19
VR Adviser
New York
$6.95M +$5.01M +150,000 New
Citadel Advisors
20
Citadel Advisors
Florida
$6.4M +$4.61M +138,138 New
ABG
21
Ally Bridge Group
New York
$5.96M +$4.29M +128,572 New
PAMU
22
Pictet Asset Management (UK)
United Kingdom
$5.79M +$4.17M +125,000 New
Schroder Investment Management Group
23
Schroder Investment Management Group
United Kingdom
$5.38M +$3.88M +116,037 New
SCM
24
Soleus Capital Management
Connecticut
$5M +$3.6M +107,826 New
CC
25
Commodore Capital
New York
$4.5M +$3.24M +97,143 New
1
2 3

SPRY Hedge Fund Activity: Q4 2020 in Review

62 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q4 2020, worth a combined $1.13B.

Buyers outnumbered sellers: 62 funds opened new SPRY positions and 0 closed out — a net gain of 62 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $292M.

  • 62 institutional investors held ARS Pharmaceuticals (SPRY) as of Q4 2020, up from 0 in Q3 2020.
  • Funds reported $1.13B of ARS Pharmaceuticals stock for Q4 2020.
  • 62 funds opened new ARS Pharmaceuticals positions in Q4 2020 and 0 closed out, a net change of +62 holders.
  • The largest ARS Pharmaceuticals buyer in Q4 2020 was OrbiMed, an estimated $292M added.

Based on aggregated 13F filings for Q4 2020.